{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:23:10Z","timestamp":1791786190286,"version":"4.3.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Several medications have been used for glucocorticoids-induced osteoporosis (GIO). However, the best therapeutic option for GIO is still controversial. A Bayesian network meta-analysis was conducted to compare the efficacy and safety of denosumab, teriparatide and bisphosphonates for patients with GIO.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Relevant randomized controlled trials published in PubMed, Embase, Cochrane Library and\n                    <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                    up to August 2023 were searched. The following efficiency and safety outcomes were extracted for comparison: bone mineral density (BMD) percentage changes in lumbar spine, femur neck and total hip, and incidences of adverse events (AEs), serious adverse events (SAEs), vertebrae and non-vertebrae fracture. Bayesian random effects models were used for multiple treatment comparisons.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    11 eligible RCTs involving 2,877 patients were identified. All the six medications including alendronate, risedronate, etidronate, zoledronate, teriparatide, and denosumab and were effective in increasing BMD. Teriparatide and denosumab were more effective in improving lumbar spine and femur neck BMD, and reducing vertebrae fracture. Alendronate and denosumab were more effective in improving total hip BMD. Alendronate and teriparatide had the lowest incidences of AEs and SAEs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Teriparatide denosumab and the bisphosphonates are all effective in improving BMD for GIO patients. Based on this network meta-analysis, teriparatide and denosumab have higher efficiency in improving lumbar spine and femur neck BMD, and reducing vertebrae fracture.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Systematic Review Registration:<\/jats:bold>\n                    <jats:ext-link>10.17605\/OSF.IO\/2G8YA<\/jats:ext-link>\n                    , identifier CRD42023456305.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2024.1336075","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T23:13:58Z","timestamp":1705619638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Liang","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1056\/NEJM199708073370603","article-title":"Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis","volume":"337","author":"Adachi","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/era.11.204","article-title":"Denosumab for the management of bone disease in patients with solid tumors","volume":"12","author":"Body","year":"2012","journal-title":"Expert Rev. anticancer Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis care and Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.bone.2009.12.032","article-title":"Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate","volume":"46","author":"Burshell","year":"2010","journal-title":"Bone"},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40842-018-0062-7","article-title":"The challenges of diagnosing osteoporosis and the limitations of currently available tools","volume":"4","author":"Choksi","year":"2018","journal-title":"Clin. Diabetes Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheumatism"},{"key":"B7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3899\/jrheum.090411","article-title":"Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis","volume":"37","author":"Devogelaer","year":"2010","journal-title":"J. Rheumatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.bone.2009.12.021","article-title":"Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate","volume":"46","author":"Eastell","year":"2010","journal-title":"Bone"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1007\/s00198-013-2379-5","article-title":"Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis","volume":"24","author":"Farahmand","year":"2013","journal-title":"Osteoporos Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial","volume":"28","author":"Gl\u00fcer","year":"2013","journal-title":"J. bone mineral Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0193846","DOI":"10.1371\/journal.pone.0193846","article-title":"The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial","volume":"13","author":"Iseri","year":"2018","journal-title":"PloS one"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1186\/s12891-022-05997-0","article-title":"Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis","volume":"23","author":"Jiang","year":"2022","journal-title":"BMC Musculoskelet. Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/14397595.2017.1362093","article-title":"Short-term daily teriparatide in patients with rheumatoid arthritis","volume":"28","author":"Kaneko","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.7326\/0003-4819-119-10-199311150-00001","article-title":"Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study","volume":"119","author":"Laan","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","article-title":"Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status","volume":"20","author":"Langdahl","year":"2009","journal-title":"Osteoporos. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","article-title":"Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis","volume":"48","author":"Lipton","year":"2011","journal-title":"Bone"},{"key":"B20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocd.2008.10.002","article-title":"Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts","volume":"12","author":"Losada","year":"2009","journal-title":"J. Clin. Densitom."},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/bmb\/ldac017","article-title":"Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis","volume":"143","author":"Migliorini","year":"2022","journal-title":"Br. Med. Bull."},{"key":"B22","doi-asserted-by":"publisher","first-page":"115902","DOI":"10.1016\/j.bone.2021.115902","article-title":"Denosumab versus alendronate in long-term glucocorticoid users: a 12-month randomized controlled trial","volume":"146","author":"Mok","year":"2021","journal-title":"Bone"},{"key":"B23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mus.27416","article-title":"The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis","volume":"64","author":"Nasomyont","year":"2021","journal-title":"Muscle and nerve"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2018-213512","article-title":"First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American group for the study of lupus (GLADEL, grupo latino Americano de Estudio del lupus)-pan-American league of associations of rheumatology (PANLAR)","volume":"77","author":"Pons-Estel","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J. bone mineral Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group","volume":"339","author":"Saag","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol. health"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/art.40156","article-title":"Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial","volume":"69","author":"Solomon","year":"2017","journal-title":"Arthritis and rheumatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif. tissue Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00198-020-05360-w","article-title":"Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis","volume":"31","author":"Wang","year":"2020","journal-title":"Osteoporos. Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"rkaa008","DOI":"10.1093\/rap\/rkaa008","article-title":"The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis","volume":"4","author":"Yamaguchi","year":"2020","journal-title":"Rheumatology Adv. Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2147\/DDDT.S148654","article-title":"Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis","volume":"13","author":"Yanbeiy","year":"2019","journal-title":"Drug Des. devel. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s13018-023-03920-4","article-title":"Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis","volume":"18","author":"Yuan","year":"2023","journal-title":"J. Orthop. Surg. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1336075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T23:14:02Z","timestamp":1705619642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1336075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":41,"alternative-id":["10.3389\/fphar.2024.1336075"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1336075","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"article-number":"1336075"}}